Literature DB >> 16464682

Down-regulation of GFRalpha-1 expression by antisense oligodeoxynucleotide attenuates electroacupuncture analgesia on heat hyperalgesia in a rat model of neuropathic pain.

Zhi-Qiang Dong1, Fei Ma, Hong Xie, Yan-Qing Wang, Gen-Cheng Wu.   

Abstract

Glial cell line-derived neurotrophic factor (GDNF) has been proved to play an important role in the modulation of nociceptive transmission especially during neuropathic pain. It was reported that electroacupuncture (EA) had potent analgesic effect on neuropathic pain and our previous studies indicated that EA could activate endogenous GDNF signaling system (GDNF and its receptor GFRalpha-1) in dorsal root ganglions (DRGs) of neuropathic pain rats. In order to investigate whether GDNF signaling system was involved in EA analgesia on neuropathic pain, which was induced by chronic constriction injury (CCI) of the sciatic nerve in rats, antisense oligodeoxynucleotide (ODN) specifically against GFRalpha-1 was used in the present study to result in down-regulation of GFRalpha-1 expression. The results showed that: (1) cumulative EA had potent analgesic effect on neuropathic pain in rats; (2) the expression of GFRalpha-1 in DRGs was down-regulated by intrathecal delivery of antisense ODN, but not by normal saline (NS) or mismatch ODN; (3) EA analgesia was significantly attenuated by antisense ODN treatment. The present study demonstrated that endogenous GDNF signaling system was involved in EA analgesia on neuropathic pain in rats, which would deepen our realization of the mechanism of EA analgesia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16464682     DOI: 10.1016/j.brainresbull.2005.08.027

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  8 in total

Review 1.  Mechanisms of acupuncture-electroacupuncture on persistent pain.

Authors:  Ruixin Zhang; Lixing Lao; Ke Ren; Brian M Berman
Journal:  Anesthesiology       Date:  2014-02       Impact factor: 7.892

2.  Effects of electroacupuncture on oxaliplatin-induced neuropathic cold hypersensitivity in rats.

Authors:  Hak Jin Moon; Bong-Soo Lim; Dae-Il Lee; Min Sook Ye; Giseog Lee; Byung-Il Min; Hyunsu Bae; Heung Sik Na; Sun Kwang Kim
Journal:  J Physiol Sci       Date:  2013-10-26       Impact factor: 2.781

3.  Effects of repeated electroacupuncture on beta-endorphin and adrencorticotropic hormone levels in the hypothalamus and pituitary in rats with chronic pain and ovariectomy.

Authors:  Jun-ling Liu; Shu-ping Chen; Yong-hui Gao; Fan-ying Meng; Shu-bin Wang; Jun-ying Wang
Journal:  Chin J Integr Med       Date:  2010-08-10       Impact factor: 1.978

Review 4.  The Role of Saponins in the Treatment of Neuropathic Pain.

Authors:  Bei Tan; Xueqing Wu; Jie Yu; Zhong Chen
Journal:  Molecules       Date:  2022-06-20       Impact factor: 4.927

5.  IB4(+) nociceptors mediate persistent muscle pain induced by GDNF.

Authors:  Pedro Alvarez; Xiaojie Chen; Oliver Bogen; Paul G Green; Jon D Levine
Journal:  J Neurophysiol       Date:  2012-08-22       Impact factor: 2.714

6.  Spinal cholinergic mechanism of the relieving effects of electroacupuncture on cold and warm allodynia in a rat model of neuropathic pain.

Authors:  Jung Hyuk Park; Sun Kwang Kim; Ha Neul Kim; Boram Sun; Sungtae Koo; Sun Mi Choi; Hyunsu Bae; Byung-Il Min
Journal:  J Physiol Sci       Date:  2009-04-03       Impact factor: 2.781

7.  Glial cell-derived neurotrophic factor attenuates neuropathic pain in a mouse model of chronic constriction injury: possible involvement of E-cadherin/p120ctn signaling.

Authors:  Cunjin Wang; Hongjun Wang; Jun Pang; Li Li; Suming Zhang; Ge Song; Na Li; Junping Cao; Licai Zhang
Journal:  J Mol Neurosci       Date:  2014-03-06       Impact factor: 3.444

8.  Synaptotagmin 1 Is Involved in Neuropathic Pain and Electroacupuncture-Mediated Analgesic Effect.

Authors:  Juan Wan; Sha Nan; Jingjing Liu; Mingxing Ding; Hongmei Zhu; Chuanguang Suo; Zhuole Wang; Manli Hu; Dehai Wang; Yi Ding
Journal:  Int J Mol Sci       Date:  2020-01-31       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.